Target price | $3.16 |
Course | $0.61 |
Price potential |
422.73%
register free of charge
|
Number of estimates | 4 |
4 Analysts have issued a price target VolitionRX 2025 .
The average VolitionRX target price is $3.16.
This is
422.73%
register free of charge
$4.00
561.16%
register free of charge
$2.30
280.17%
register free of charge
|
|
A rating was issued by 4 analysts: 3 Analysts recommend VolitionRX to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst estimates: Analysts believe that the VolitionRX share has an average upside potential 2025 of
422.73%
register free of charge
|
Dec '23 |
2024 Forecast |
|
---|---|---|
Turnover Million $ | 0.78 | 2.87 |
151.61% | 268.50% | |
EBITDA margin | -4,433.33% | -1,113.32% |
55.07% | 74.89% | |
Net margin | -5,263.46% | -1,035.56% |
63.87% | 80.33% |
5 Analysts have issued a sales forecast VolitionRX 2024 . The average VolitionRX sales estimate is
This results in the following potential growth figures:
1 Analyst has issued an EBITDA forecast VolitionRX 2024 . The average VolitionRX EBITDA estimate is
This results in the following potential growth figures and future EBITDA margins:
4 VolitionRX Analysts have issued a net profit forecast 2024. The average VolitionRX net profit estimate is
This results in the following potential growth figures and future net margins:
Dec '23 |
2024 Forecast |
|
---|---|---|
Earnings per share $ | -0.50 | -0.36 |
9.09% | 28.00% | |
P/E ratio | negative | |
EV/Sales | 14.94 |
4 Analysts have issued a VolitionRX forecast for earnings per share. The average VolitionRX <a href=/blog/eps>EPS is
This results in the following potential growth figures and future valuations:
Based on analysts' sales estimates for 2024, the VolitionRX share is valued at an <a href=/blog/ev-sales-einfach-erklaert>EV/Sales of
This results in the following potential growth figures and future valuations:
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.